PTC Therapeutics shared the below letter to the Duchenne community. We are pleased to see the results of the dystrophin study (Study 045) and thankful for PTC’s longtime commitment to the Duchenne community.
CureDuchenne continues to lead the patient community in funding the Duchenne drug development pipeline, with a new investment in Entrada Therapeutics
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort
PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference
Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy
Make an Impact
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.Donate